First look at psoriasis drug for kids tests single dose
NCT ID NCT03240809
Summary
This study is checking the safety and how the body processes a single dose of the drug brodalumab in children aged 6 to 18 with severe plaque psoriasis. It is a small, early-stage study designed to gather initial safety information. The main goal is to see how much of the drug gets into the bloodstream and to watch for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Bausch Site 001
Las Vegas, Nevada, 45242, United States
-
Bausch Site 002
Miami, Florida, 33155, United States
-
Bausch Site 003
San Diego, California, 92123, United States
-
Bausch Site 004
Miami, Florida, 33155, United States
-
Bausch Site 005
Henderson, Nevada, 89052, United States
Conditions
Explore the condition pages connected to this study.